ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IRD vs PRLD // NET PROFIT MARGIN

Opus Genetics Inc. (NASDAQ) VS. Prelude Therapeutics Incorporated (NASDAQ) • 15-METRIC TALLY: IRD 2 — PRLD 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRD VS. PRLD) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IRD PRLD SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -11.61% -17.23% +5.62 IRD /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin ACTIVE -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 29.10% 73.40% -44.30 PRLD /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 4/9 +1.00 IRD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.0 48.9 -8.90 PRLD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $305.3M $309.6M -$4.3M PRLD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IRD REV PRLD REV IRD GROSS % PRLD GROSS % IRD FCF PRLD FCF
FY 2025 $14.2M $12.1M — — -$35.3M -$56.4M
FY 2024 $11.0M $7.0M — — -$25.6M -$103.7M
FY 2023 $19.0M $370.4M — — -$1.1M -$107.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRD // BETA —
PRLD // BETA —